Swedish Pharma Co. Targets US Partner In Arbitration

Law360 (June 15, 2020, 8:41 PM EDT) -- The Swedish biopharmaceutical company Camurus AB is looking to terminate a licensing agreement with the opioid addiction drug company Braeburn Inc. to commercialize Camurus' drugs in North America, accusing the U.S. company of breaching the deal in arbitration it initiated in England.

Camurus said the dispute has to do with Braeburn's efforts to prepare for the regulatory approval and commercialization in the United States and Canada of Brixadi, an injection used to treat opioid dependence. It also stems from the company's efforts to develop and prepare for the commercialization of CAM2038, a drug used to treat chronic pain.

Camurus announced on...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!